Abstracts

• Fitzgerald T, Hermsen ED, Sholtz LA, Anderson JR, Iwen PC, Jourdan D, Marion N, Rupp ME. Multi-disciplinary Interventions for the Management and Prevention of Clostridium difficile-Associated Disease at an Academic Medical Center. Accepted abstract, Poster Presentation, Annual Conference of the Association for Professionals in Infection Control, Denver, CO, June 15 – June 19, 2008.
• Hermsen ED, Shull SS, Parizek L, Qiu F, Wilderman J, Rupp ME. Outcomes of a Pharmacist-Initiated Antimicrobial Step-Down Protocol. Accepted abstract, Poster Presentation, Annual Meeting of the American College of Clinical Pharmacy, Denver, CO, October 14 – October 17, 2007.
• Hermsen ED, Shull SS, Parizek L, Qiu F, Wilderman J, Rupp ME. Antimicrobial Step-Down Conversion on a General Medicine Ward. Accepted abstract, Oral Presentation, 45th Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, October 4 – October 7, 2007.
• Hermsen ED, Shull SS, Klepser DG, Iwen PC, Armbrust A, Garrett J, Freifeld AG, Rupp ME. Pharmacoeconomic analysis of microbiologic techniques for differentiating Gram-positive cocci in clusters (GPCC) directly from blood culture bottles. Accepted abstract, Poster Presentation, 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 17 – September 20, 2007.
• Hermsen ED, Mitropoulos IF, Shull SS, Puumala S, Rupp ME. Prospective evaluation of clinical and economic outcomes associated with treatment of serious infections due to Gram-positive cocci (GPC). Accepted abstract, Poster Presentation, 44th Annual Meeting of the Infectious Diseases Society of America, Toronto, Ontario, Canada, October 12 – October 15, 2006.
• Hermsen ED, Shull SS, Puumala S, Rupp ME. Comparative evaluation of clinical and economic parameters of an antimicrobial surgical prophylaxis (ASP) order form. Accepted abstract, Poster Presentation, 44th Annual Meeting of the Infectious Diseases Society of America, Toronto, Ontario, Canada, October 12 – October 15, 2006.
• Erlandson KM, Sun J, Iwen P, Rupp ME. Impact of More Potent Antibiotics on Outcome Measures of Patients with Vancomycin-Resistant Enterococcus (VRE) Bacteremia, Accepted abstract, Poster Presentation, 44th Annual Meeting of the Infectious Diseases Society of America, Toronto, Ontario, Canada, October 12 – October 15, 2006.
• Hermsen ED, Shull SS. Coagulase-Negative Staphylococci Contaminated Blood Cultures and Associated Costs. Accepted abstract, Poster Presentation, 43rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, October 6 – October 9, 2005.

Publications

• Hermsen ED, Shull SS, Parizek L, Qiu F, Wilderman J, Rupp ME. Outcomes of a pharmacist-initiated step-down protocol for antimicrobials. (Submitted 2008)
• O’Grady NP, Alexander M, Burns LA, Dellinger EP, Garland J, Heard SO, Lipsett P, Maki DG, Masur H, Mermel LA, Pearson ML. Raad II, Randolph A, Rupp ME, Saint S. Guidelines for the prevention of intravascular catheter-related Infections. (Submitted 2008).
• Hermsen ED, Shull SS, Klepser DG, Iwen PC, Armbrust A, Garrett J, Freifeld AG, Rupp ME. Pharmacoeconomic analysis of microbiologic techniques for differentiating staphylococci directly from blood culture bottles. Journal of Clinical Microbiology (In press).
• Hermsen ED, Shull SS, Mitropoulos IF, Puumala SE, Rupp ME. Prospective Evaluation of Clinical and Economic Outcomes Associated with Treatment of Serious Infections due to Gram-positive Cocci. Infectious Diseases in Clinical Practice (In press).
• Hermsen ED, Shull SS, Puumala SE, Rupp ME. Improvement in clinical and economic outcomes associated with the introduction of a standardized approach for surgical antimicrobial prophylaxis. Infection Control and Hospital Epidemiology. 2008;29:457-61.
• Erlandson KM, Sun J, Iwen PC, Rupp ME. Impact of more potent antibiotics linezolid and quinuprisitn/dalfopristin on outcome measures of patients with vancomycin-resistant Enterococcus bacteremia. Clinical Infectious Diseases. 46:30-6, 2008.
• Rupp ME, Fitzgerald T, Puumala S, Anderson JR, Craig R, Iwen PC, Jourdan D, Keuchel J, Marion N, Peterson D, Sholtz L, Smith V. Prospective, controlled, cross-over trial of alcohol-based hand gel in critical care units. Infection Control and Hospital Epidemiology. 29:8-15, 2008.
• Cosgrove SE, Boucher HW, Vigliani GA, Campion M, Fowler VG, Abrutyn E, Corey GR, Rupp ME, Chambers HF, Karchmer AW. Initial low-dose gentamicin in the treatment of Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. (Submitted 2007).
• Hermsen ED, Garr M, Reisbig K, Friedig W, Maiefski M, Walker R, Rupp ME. CA-MRSA is thriving in Nebraska. Physicians Bulletin. 2007 (November/December), page 9.
• Hermsen ED, Garr M, Reisbig K, Maiefski M, Walker R, Rupp ME. CA-MRSA is thriving in Nebraska. Cornhusker Family Physician. 2007;53:54-5.
• Rupp ME, Holley HP, Jr, Lutz P, Dicpinigaitis PV, Woods C, Levine DP, Veney N, Fowler VG, Jr. A phase II, randomized, multicenter, double-blind, placebo-controlled, trial of a polyclonal anti-capsular immunoglobin in the treatment of Staphylococcus aureus bacteremia. Antimicrobial Agents and Chemotherapy. 51:4249-54, 2007.
• Rupp ME, Lee SA, Jourdan DR, Marion ND, Tyner LK, Fey PD, Iwen PC, Anderson JR. Outbreak of bloodstream infections temporally associated with the use of an intravascular positive-displacement needleless valve Clinical Infectious Diseases. 44:1408-14, 2007.
• Fowler VG, Boucher HW, Corey R, Abrutyn E, Karchmer AW, Rupp ME. Levine DM, Chambers HF, Talley FP, Vigliani G, Cabell CH, Link AS, DeMeyer I, Filler S, Zervos M, Cook P, Parsonnet J, Berstein JM, Price CS, Forrest G, Fatkenheur G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE & S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for Staphylococcus aureus bacteremia and endocarditis. N Eng J Med. 355:653-65, 2006.
• Rupp ME, Lisco S, Lipsett P, Perl T, Keating K, Civetta J, Mermel L, Lee D, Dellinger EP, Donahoe M, Giles D, Pfaller M, Maki DG, Sherertz R. Effect of a second-generation chlorhexidine/silver sulfadiazine-impregnated central venous catheter on catheter-associated infections in intensive care unit patients. A randomized, double-blinded, controlled trial. Annals of Internal Medicine. 143:570-580, 2005.
• Rupp ME, Fitzgerald T, Marion N, Helget V, Puumala S, Anderson JR, Fey PD. Effect of silver-coated urinary catheters: efficacy, cost-effectiveness, and antimicrobial resistance. American Journal of Infection Control. 32:445-450, 2004.